JP2017081912A - 傷口の癒合、コラーゲン増殖、血管新生、免疫細胞の活性化を促進し、また傷口の感染を減少させることができるペプチド及びその応用 - Google Patents
傷口の癒合、コラーゲン増殖、血管新生、免疫細胞の活性化を促進し、また傷口の感染を減少させることができるペプチド及びその応用 Download PDFInfo
- Publication number
- JP2017081912A JP2017081912A JP2016209132A JP2016209132A JP2017081912A JP 2017081912 A JP2017081912 A JP 2017081912A JP 2016209132 A JP2016209132 A JP 2016209132A JP 2016209132 A JP2016209132 A JP 2016209132A JP 2017081912 A JP2017081912 A JP 2017081912A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- peptides
- wound
- present
- immune cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 86
- 102000008186 Collagen Human genes 0.000 title claims abstract description 14
- 108010035532 Collagen Proteins 0.000 title claims abstract description 14
- 229920001436 collagen Polymers 0.000 title claims abstract description 14
- 230000029663 wound healing Effects 0.000 title claims abstract description 11
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 8
- 206010048038 Wound infection Diseases 0.000 title claims abstract description 7
- 230000005931 immune cell recruitment Effects 0.000 title claims abstract description 7
- 230000035755 proliferation Effects 0.000 title claims abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 23
- 210000002865 immune cell Anatomy 0.000 claims description 12
- 239000007952 growth promoter Substances 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 7
- 239000012190 activator Substances 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 230000001603 reducing effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 238000011084 recovery Methods 0.000 abstract description 3
- 238000001356 surgical procedure Methods 0.000 abstract description 2
- 241000269795 Lateolabrax japonicus Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002434 immunopotentiative effect Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 33
- 239000002158 endotoxin Substances 0.000 description 27
- 229920006008 lipopolysaccharide Polymers 0.000 description 27
- 208000027418 Wounds and injury Diseases 0.000 description 25
- 206010052428 Wound Diseases 0.000 description 24
- 206010036790 Productive cough Diseases 0.000 description 18
- 210000003802 sputum Anatomy 0.000 description 18
- 208000024794 sputum Diseases 0.000 description 18
- 239000000284 extract Substances 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 14
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 13
- 230000006698 induction Effects 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 13
- 238000010586 diagram Methods 0.000 description 12
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 8
- 102000004890 Interleukin-8 Human genes 0.000 description 8
- 108090001007 Interleukin-8 Proteins 0.000 description 8
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 8
- 102000003814 Interleukin-10 Human genes 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 241000972773 Aulopiformes Species 0.000 description 6
- 235000019515 salmon Nutrition 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000037314 wound repair Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000001804 debridement Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 108010004032 Bromelains Proteins 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 102000005158 Subtilisins Human genes 0.000 description 2
- 108010056079 Subtilisins Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000019835 bromelain Nutrition 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 108010059345 keratinase Proteins 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108010009355 microbial metalloproteinases Proteins 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000004071 soot Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000006444 vascular growth Effects 0.000 description 2
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000723298 Dicentrarchus labrax Species 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000021289 health related food Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Epidemiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Marine Sciences & Fisheries (AREA)
Abstract
Description
まず、鱸をスライスマシンで約2〜6cmの大きさに切って原料とする。当該鱸の部位は皮、鱗、骨及び肉を含む。そして、2〜5倍の体積のRO逆浸透水で原料を洗浄し、2〜3回繰り返し洗浄して血や不純物を取り除く。
鱸の抽出物を適切に希釈した後、遠心分離(13000rpm、2min)によって200μlの上澄み液を吸い取り、C18−ZipTip(Millpore)で脱塩濃縮し、サンプル溶解後1/2の体積を取り、以下の条件でLC−MS/MS分析を行う。MS/MSスペクトルは、Mascot解析プログラムを使ってデータベースを検索し、解析を行い、解析結果を得る。
質量分析計 : LTQ XL (Thermo Scientific)
LCシステム : Agilent 1200 Series
緩衝液A : ddH2O / 0.1% formic acid
緩衝液B : 100% ACN / 0.1% formic acid
分析カラム : C18 reverse phase column
ヒトのTHP−1細胞(ヒト単球系細胞株)を6ウェルの細胞培養プレート(5*105cell/well)でそれぞれ培養し、且つそれをグループ分けして個別にリポ多糖(Lipopolysaccharide,以下LPSという)処理を行う。処理方法は表3に示す通りである。
Claims (9)
- 傷口の癒合、コラーゲン増殖、血管新生、免疫細胞の活性化を促進し、また傷口の感染を減少させることができるペプチドであって、当該ペプチドはSEQ ID NO:1〜SEQ ID NO:11、及びその組み合わせのペプチドで構成されるグループから選択されたものを含む。
- 傷口の癒合促進の用途に用いるペプチドであって、当該ペプチドは請求項1に記載のペプチドを含む。
- 請求項1に記載のペプチドを含む傷口の癒合促進剤。
- コラーゲン増殖促進の用途に用いるペプチドであって、当該ペプチドは請求項1に記載のペプチドを含む。
- 請求項1に記載のペプチドを含むコラーゲン増殖促進剤。
- 血管増殖促進の用途に用いるペプチドであって、当該ペプチドは請求項1に記載のペプチドを含む。
- 請求項1に記載のペプチドを含む血管増殖促進剤。
- 免疫細胞活性化の用途に用いるペプチドであって、当該ペプチドは請求項1に記載のペプチドを含む。
- 請求項1に記載のペプチドを含む免疫細胞活性化剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW104135487A TWI612057B (zh) | 2015-10-28 | 2015-10-28 | 可促進傷口癒合、膠原蛋白增生、血管新生、活化免疫細胞並降低傷口感染之胜肽及其應用 |
TW104135487 | 2015-10-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017081912A true JP2017081912A (ja) | 2017-05-18 |
JP6650861B2 JP6650861B2 (ja) | 2020-02-19 |
Family
ID=58635339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016209132A Active JP6650861B2 (ja) | 2015-10-28 | 2016-10-26 | 傷口の癒合、コラーゲン増殖、血管新生、免疫細胞の活性化を促進し、また傷口の感染を減少させることができるペプチド及びその応用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10005823B2 (ja) |
JP (1) | JP6650861B2 (ja) |
KR (1) | KR20170049432A (ja) |
CN (1) | CN106632641B (ja) |
TW (1) | TWI612057B (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107164442B (zh) * | 2017-06-05 | 2020-10-13 | 深圳知本康业有限公司 | 一种胶原蛋白多肽及应用 |
CN107383164B (zh) * | 2017-07-03 | 2019-10-11 | 择天生物科技(大连)有限公司 | 一类用于促胶原分泌的超短肽及其应用 |
US10758559B1 (en) | 2017-09-01 | 2020-09-01 | University Of Wyoming | Targeting cathepsin K to facilitate wound healing |
US11766467B2 (en) | 2017-09-01 | 2023-09-26 | University Of Wyoming | Methods of treating wounds using cathepsin K inhibitors |
US10232009B1 (en) * | 2017-09-29 | 2019-03-19 | Pro Sunfun Biotech Research And Development Co., Ltd. | Peptide for promoting wound healing, its composition and method of using the same |
TWI674276B (zh) * | 2017-09-29 | 2019-10-11 | 三凡生技研發股份有限公司 | 促進傷口癒合之胜肽、其組合物及其使用方法 |
JP7387603B2 (ja) * | 2017-11-29 | 2023-11-28 | フィジーン、エルエルシー | 活性化のための線維芽細胞と免疫細胞との相互作用及びそれらの使用 |
WO2023200875A1 (en) * | 2022-04-13 | 2023-10-19 | ALASTIN Skincare, Inc. | Octapeptide for topical application |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8298548B2 (en) * | 2007-07-18 | 2012-10-30 | Solazyme, Inc. | Compositions for improving the health and appearance of skin |
CN101113171A (zh) * | 2006-07-26 | 2008-01-30 | 吴金洌 | 一种用以增加动物摄食量的胜肽 |
CN104491845A (zh) * | 2008-04-18 | 2015-04-08 | 科尔普兰特有限公司 | 产生和使用原胶原的方法 |
US8349799B1 (en) * | 2012-01-07 | 2013-01-08 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
CN104248751A (zh) * | 2013-06-28 | 2014-12-31 | 东吴大学 | 抗癌胜肽、其用途以及含有该胜肽的医药组成物 |
CN104293868A (zh) * | 2013-07-18 | 2015-01-21 | 张明焕 | 鱼鳞胶原蛋白胜肽的制备方法 |
-
2015
- 2015-10-28 TW TW104135487A patent/TWI612057B/zh active
-
2016
- 2016-01-26 CN CN201610051300.1A patent/CN106632641B/zh active Active
- 2016-10-26 JP JP2016209132A patent/JP6650861B2/ja active Active
- 2016-10-27 KR KR1020160141003A patent/KR20170049432A/ko unknown
- 2016-10-27 US US15/336,212 patent/US10005823B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
TWI612057B (zh) | 2018-01-21 |
CN106632641A (zh) | 2017-05-10 |
JP6650861B2 (ja) | 2020-02-19 |
KR20170049432A (ko) | 2017-05-10 |
US10005823B2 (en) | 2018-06-26 |
CN106632641B (zh) | 2019-10-18 |
US20170121378A1 (en) | 2017-05-04 |
TW201714893A (zh) | 2017-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6650861B2 (ja) | 傷口の癒合、コラーゲン増殖、血管新生、免疫細胞の活性化を促進し、また傷口の感染を減少させることができるペプチド及びその応用 | |
US10455849B2 (en) | Method for the preparation of a protein peptide, a protein peptide and use thereof | |
CN106519020B (zh) | 一种具有美容功效的功能性肽及其制备方法和用途 | |
TWI516212B (zh) | 結合壓力與酵素萃取燕窩之方法 | |
CN104710511B (zh) | 一种源于带鱼鱼肉蛋白的铁螯合肽及其制备方法和用途 | |
CN104513843A (zh) | 一种多糖和蛋白肽的联合制备方法 | |
CN103305580A (zh) | 一种以哺乳动物皮及骨为原料制备胶原蛋白肽的方法 | |
CN104357522A (zh) | 一种利用大鲵的蜕皮提取胶原蛋白的方法 | |
CN108929891B (zh) | 一种鲎血血细胞蛋白活性肽的制备方法 | |
JP2012244930A (ja) | かつおの中骨を原料とするコラーゲンペプチドの製造方法 | |
CN107082807B (zh) | 具有ace抑制功能的牦牛骨蛋白肽及制备方法和应用 | |
CN109457007A (zh) | 一种胸腺肽的制备方法 | |
CN113151385B (zh) | 一种制备畜禽软骨胶原蛋白多肽的方法 | |
CN101948898B (zh) | 一种纳米胶原寡肽的制备方法 | |
CN101756237B (zh) | 马氏珍珠贝肉抗高血压功能营养液生产方法 | |
CN109439716B (zh) | 一种白鲢鱼蛋白肽的制备方法 | |
CN115724907B (zh) | 红托竹荪多肽及其应用 | |
JP2009284798A (ja) | ジペプチジルペプチダーゼiv阻害剤の製造方法 | |
KARAOĞUL et al. | Foods that improving the Immune System against Covid-19 and its infectiousness: Foods against Covid-19 and its infectiousness | |
CN112442112B (zh) | 一种银杏蛋白源ace抑制肽组合物及其制备方法和应用 | |
TWI617315B (zh) | 具有護骨功效之鱸魚萃取物 | |
JP2001163896A (ja) | アンギオテンシン変換酵素阻害剤として用いられる新規ペプチド及びその製造方法 | |
Triastuti et al. | Extraction and purification of bromelain enzyme from queen pineapple | |
CN114591397B (zh) | 具有降血压功能的多肽及其制备方法 | |
CN107630062B (zh) | 一种线纹海马ace抑制肽的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161026 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170227 |
|
AA79 | Non-delivery of priority document |
Free format text: JAPANESE INTERMEDIATE CODE: A24379 Effective date: 20170307 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170627 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170927 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171222 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180320 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180718 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180724 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20180817 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190807 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190909 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191007 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191028 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200121 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6650861 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |